A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus - Trial 2022-003318-35
Access comprehensive clinical trial information for 2022-003318-35 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Ongoing. The study focuses on Type 1 Diabetes Mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2022-003318-35
Ongoing
Trial Details
EU Clinical Trials Register • 2022-003318-35
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
Study Focus
Sponsor & Location
Vertex Pharmaceuticals Incorporated
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1. Prior islet cell transplant, organ transplant, or cell therapy.
ICD-10 Classifications
Type 1 diabetes mellitus
Type 1 diabetes mellitus with unspecified complications
Type 1 diabetes mellitus with other specified complications
Type 1 diabetes mellitus without complications
Type 1 diabetes mellitus with multiple complications
Data Source
EU Clinical Trials Register
2022-003318-35
Non-Device Trial